



118 YEARS STRONG

Since our founding in 1905,
we've pioneered scientific
advancements in the
nourishment of **preterm
infants**...helping them
grow and thrive.



reckitt®

MeadJohnson
Nutrition



Enfamil® DHA & ARA Supplement is the **ONLY** fat modular with DHA & ARA specifically for preterm infants.

Backed by science:

- Enfamil® DHA & ARA Supplement is a sterile, emulsified product with 4 calories per 1 mL
- DHA & ARA supplementation in very low birth weight infants has been shown to support growth, reduce retinopathy of prematurity, and improve respiratory outcomes¹⁻³
- Use of Enfamil® DHA & ARA Supplement has been shown to increase blood amounts of DHA and ARA and maintain expert recommended ratio of 1:2^{4,5}
- Does not impact osmolality



Enfamil® Liquid Human Milk Fortifier is the **ONLY** fortifier to meet aseptic technique guidelines and expert recommendations for iron.⁶



Driven by innovation:

- Safe, well tolerated, & supports growth⁷
- Minimizes breast milk displacement when compared to other liquid human milk fortifiers⁸
- Allows clinicians the flexibility to target protein levels of lower protein donor human milk and higher protein preterm human milk⁹
- The only leading brand to maintain recommended osmolality from 22 to 30 calories per ounce¹⁰
- Survey respondents perceived improvements in efficiency, accuracy, ease, and waste reduction compared with previous human milk fortification products¹¹
- Provides higher amounts of vitamin D and iron than Similac® Extensively Hydrolyzed Human Milk Fortifier*

Enfamil® Liquid Human Milk Fortifier has been used in over 10 million feedings to over 50,000 babies since launch in 2020¹²

*Vitamin D (ELHMF: 47 IU/5 ml vs Similac HMF: 35 IU/5 ml); iron (ELHMF: 0.44 mg/5 ml vs Similac HMF: 0.11 mg/5 ml)

Enfamil® Premature is the **ONLY** premature portfolio designed to meet 2021 Global Recommendations for all labeled nutrients.⁵



Guided by experts:

NUTRIENT (per 100 kcal)	2021 GLOBAL EXPERT RECOMMENDATION ⁵	ENFAMIL® PREMATURE (20, 24, 24HP, 30 CAL)	SIMILAC® SPECIAL CARE® (20, 24, 24HP, 30 CAL)
Choline	≥30 mg	30 mg	10 mg
Zinc	1.8-2.7 mg	1.8 mg	1.5 mg
Selenium	6.4-9.1 mcg	6.4 mcg	2 mcg

Enfamil® NeuroPro™ EnfaCare® is the **ONLY** leading premature transition formula that meets expert guidelines for calcium and phosphorus, and has a whey-to-casein ratio modeled after early breast milk.^{5,13*}



Supported by research:

NUTRIENT (per 100 kcal)	PRETERM NUTRITION EXPERT GUIDELINES ⁵	ENFAMIL NEUROPRO™ ENFACARE®	SIMILAC® NEOSURE®
Calcium	109-200 mg	120 mg	105 mg
Phosphorus	64-109 mg	66 mg	62 mg

	EARLY BREAST MILK	ENFAMIL NEUROPRO™ ENFACARE®	SIMILAC® NEOSURE®
Whey-to-casein ratio	80:20 ¹³	80:20	50:50

Enfamil® Premature and EnfaCare® have not been shown superior to Similac® Special Care® and Similac® NeoSure® in supporting premature infant's growth and development.



Our Helping Hands™ program can help patients get reimbursed through government programs or insurance



MFGM = milk fat globule membrane

*Based on whey-to-casein ratio of early breast milk (3 to 5 days after lactation begins).

†Enfamil NeuroPro™ EnfaCare® has MFGM from whey protein concentrate.

‡WIC® is a registered trademark of the United States Department of Agriculture (USDA) for the Women, Infants, and Children Program.

No endorsement of any brand or product by the USDA is implied or intended.

Science is our **STRENGTH**

For 118 years, we have led scientific advancements in infant nutrition, helping the most vulnerable infants to safely grow, develop, and thrive.



Your goal is our goal: **to make every mL count.**



Promote growth with the Enfamil® NICU portfolio.
Contact your representative for more information.

Enfamil® Premature has not been shown superior to Similac® Special Care® in supporting infant's cognitive or immune development.
Enfamil NeuroPro™ EnfaCare® has not been shown superior to Similac® NeoSure® in supporting infant's digestion or bone development.
*Among those who have a preference.

REFERENCES: 1. Frost B, MacKendrick W. Gender-specific effects of long chain polyunsaturated fatty acid (LCPUFA) supplementation in very low birth weight (VLBW) infants. [abstract]. Supporting Information. PAS Meeting: April 28, 2023, Washington, DC. 2. Hellstrom A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. *JAMA Pediatr.* 2021;175(4):359-367. 3. Wendel K, Aas MF, Gunnarsdottir G, et al. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants. *Clin Nutr.* 2023;42(1):22-28. 4. Frost BL, Patel AL, Robinson DT, Berseth CL, Cooper T, Caplan M. Randomized controlled trial of early docosahexaenoic acid and arachidonic acid enteral supplementation in very low birth weight infants. *J Pediatr.* 2021;232:23-30.e1. 5. Koletzko B, Cheah FC, Domellöf M, van Goudoever JB, Poindexter BB, Vain N. Scientific basis and practical application of nutritional care for preterm infants. *World Rev Nutr Diet.* 2021;122:XIII-XIV. 6. Steele C, Collins E. Infant and Pediatric Feedings: Guidelines for Preparation of Human Milk and Formula in Health Care Facilities. 3rd ed. *Academy of Nutrition and Dietetics*; 2018. 7. Moya F, Fowler J, Florens A, Frank K, Dombrowski J, Davis O, Blanks, T, Gratton A. Human milk fortification: impact of a new fortifier on growth velocity and tolerance; a retrospective study. [abstract]. Supporting Information. PAS Meeting: April 29, 2023, Washington, DC. 8. Bingham R, Pineda D, Gates A, Thompson AB, Stansfield BK. Displacement of human milk during fortification: an experimental study. *JPEN J Parenter Enteral Nutr.* 2023;10.1002/jpen.2553. 9. A. Gates, A.B. Hair, A.A. Salas, A.B. Thompson, B.K. Stansfield, Nutrient composition of donor human milk and comparisons to preterm human milk, *The Journal of Nutrition*, <https://doi.org/10.1016/j.tjnut.2023.07.012>. 10. Pineda D, Bingham RE, Thompson A, Gates A, Stansfield B. Osmolality of fortified donor human milk. *Am J Med Sci.* 2023;365:S300-S301. 11. Gates A, Evans HV, Gatto AM, et al. Perceptions of the impact of a multidose human-milk fortifier on human-milk preparation practices in United States neonatal intensive care units: A survey of nutrition care team members. *Nutr Clin Pract.* 2023;38(4):914-923. 12. Data on file. 13. Kunz C, Lönnerdal B. Re-evaluation of the whey protein/casein ratio of human milk. *Acta Paediatr.* 1992;81(2):107-112.

The third party trademarks used herein are trademarks of their respective owners.

LA5481 08/23 ©2023 Mead Johnson & Company, LLC.

